In October 2020, Mallinckrodt filed for bankruptcy in all of its U.S. subsidiaries with the plan of quelling its debt by about $1.3 billion after resolving opioid-related claims and litigation involving its drug Acthar, a multiple sclerosis and seizure medication. The company settled for $260 million over claims it knowingly underpaid CMS for Acthar.
After restructuring its financials during the Chapter 11 bankruptcy, Mallinckrodt reduced its total debt by about $1.9 billion, it said in a news release.
“Mallinckrodt has emerged from this process as a stronger company, better positioned to advance our strategic and operational initiatives and achieve long-term success,” Siggi Olafsson, president and CEO of Mallinckrodt, said in the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
